Traders Purchase High Volume of Boston Scientific Call Options (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 111,780 call options on the stock. This represents an increase of approximately 661% compared to the typical volume of 14,694 call options.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BSX shares. Oppenheimer decreased their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group dropped their price objective on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Barclays lifted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Finally, Wells Fargo & Company raised their price target on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Boston Scientific presently has an average rating of “Buy” and a consensus price target of $123.89.

Insider Transactions at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 93,095 shares of company stock worth $9,305,450 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BSX. Signaturefd LLC grew its position in Boston Scientific by 0.5% during the fourth quarter. Signaturefd LLC now owns 31,429 shares of the medical equipment provider’s stock worth $2,997,000 after buying an additional 156 shares during the period. Savvy Advisors Inc. grew its holdings in shares of Boston Scientific by 56.0% in the 4th quarter. Savvy Advisors Inc. now owns 22,361 shares of the medical equipment provider’s stock worth $2,132,000 after acquiring an additional 8,024 shares during the period. Jackson Wealth Management LLC increased its stake in Boston Scientific by 1.8% in the 4th quarter. Jackson Wealth Management LLC now owns 47,607 shares of the medical equipment provider’s stock valued at $4,539,000 after purchasing an additional 842 shares in the last quarter. Perpetual Ltd boosted its position in Boston Scientific by 42.4% during the fourth quarter. Perpetual Ltd now owns 5,421 shares of the medical equipment provider’s stock worth $517,000 after purchasing an additional 1,613 shares in the last quarter. Finally, American National Bank & Trust grew its holdings in Boston Scientific by 5.6% in the fourth quarter. American National Bank & Trust now owns 5,321 shares of the medical equipment provider’s stock valued at $507,000 after purchasing an additional 280 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock traded up $3.10 during mid-day trading on Tuesday, hitting $91.17. 13,500,971 shares of the stock were exchanged, compared to its average volume of 11,105,550. The stock’s fifty day simple moving average is $96.65 and its two-hundred day simple moving average is $100.16. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific has a 12-month low of $85.98 and a 12-month high of $109.50. The stock has a market capitalization of $135.15 billion, a price-to-earnings ratio of 48.67, a P/E/G ratio of 1.56 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.